Acadia Healthcare Company, Inc.

Listed Company

ACHCCIK 0001520697NasdaqLarge AcceleratedServices-Specialty Outpatient Facilities, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.31B

Net Income

$-1.10B

Total Assets

$5.53B

Equity

$1.95B

Shares Out

90.76M

Op. Cash Flow

$131.90M

Business

Acadia Healthcare Company, Inc. provides behavioral healthcare services focused on high-acuity and complex needs patients across the continuum of care. It offers acute inpatient psychiatric care, specialty treatment (including substance use disorder and eating disorder programs), comprehensive treatment centers that deliver medication‑assisted outpatient therapy, and residential treatment centers with associated outpatient programs. Its operations are organized by service lines including acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs) and residential treatment centers. The company operates a national network of facilities distributed across multiple states and territories and serves patients through referrals, payer programs and direct admissions.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	3,313	3,154	2,929	2,610	2,314
Salaries, wages and benefits (including equity-based compensation expense of $31,708, $37,113, and $32,289, respectively)	1,821	1,691	1,572	1,393	1,244
Professional fees	195	190	176	158	137
Supplies	118	113	106	100	91
Rents and leases	48	48	47	45	39
Other operating expenses	553	441	389	349	301
Income from provider relief fund	—	—	−6	−21	−18
Depreciation and amortization	189	150	132	118	107
Interest expense, net	139	116	82	70	77
Debt extinguishment costs	1	—	—	—	25
Legal settlements expense	151	—	394	—	—
Loss on impairment	1,008	17	10	—	24
Gain on sale of property	−9	—	−10	—	—
Transaction, legal and other costs	164	47	62	24	13
Total expenses	4,379	2,812	2,954	2,236	2,039
(Loss) income before income taxes	−1,066	342	−25	374	276
Provision for (benefit from) income taxes	26	77	−10	94	68
Net (loss) income	−1,092	264	−16	280	196
Net income attributable to noncontrolling interests	−11	−9	−6	−7	−5
Net (loss) income attributable to Acadia Healthcare Company, Inc.	−1,103	256	−22	273	191
Basic (per share)	−12.16	2.79	−0.24	3.05	2.15
Diluted (per share)	−12.16	2.78	−0.24	2.98	2.1
Basic (shares)	91	92	91	90	89
Diluted (shares)	91	92	91	92	91

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	133	76	100	98	134
Accounts receivable, net	441	365	361	322	281
Other current assets	240	136	134	86	80
Total current assets	814	577	596	506	495
Property and equipment, net	3,111	2,853	2,267	1,952	1,771
Goodwill	1,296	2,265	2,226	2,223	2,200
Intangible assets, net	97	70	73	76	70
Deferred tax assets	3	21	7	3	3
Operating lease right-of-use assets	134	118	118	135	134
Other assets	73	52	73	93	95
Total assets	5,527	5,957	5,359	4,988	4,768
Current portion of long-term debt	28	77	29	21	19
Accounts payable	150	233	156	105	99
Accrued salaries and benefits	189	155	142	125	138
Current portion of operating lease liabilities	21	25	26	26	23
Other accrued liabilities	137	88	532	111	126
Total current liabilities	525	578	886	388	405
Long-term debt	2,472	1,880	1,343	1,365	1,479
Deferred tax liabilities	67	84	2	93	74
Operating lease liabilities	122	102	101	116	117
Other liabilities	202	122	140	125	111
Total liabilities	3,387	2,766	2,471	2,087	2,185
Redeemable noncontrolling interests	192	117	106	88	65
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued	—	—	—	—	—
Common stock, $0.01 par value; 180,000,000 shares authorized;90,452,843 and 91,775,264 issued and outstanding as of December 31, 2025 and 2024, respectively	905,000	918,000	913,000	899,000	890,000
Additional paid-in capital	2,714	2,685	2,649	2,658	2,636
(Accumulated deficit) retained earnings	−766	387	132	153	−120
Total equity	1,949	3,074	2,782	2,813	2,517
Total liabilities and equity	5,527	5,957	5,359	4,988	4,768

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Amortization of debt issuance costs	5	4	3	3	4
Deferred income taxes	1	68	−94	17	12
Non-cash legal settlements expense	4	—	394	—	—
Other	2	−5	3	3	491,000
Accounts receivable, net	−75	−2	−39	−42	2
Other current assets	−47	−7	9	−18	2
Other assets	−11	521,000	989,000	2	−11
Accounts payable and other accrued liabilities	15	−421	17	5	6
Accrued salaries and benefits	27	12	17	7	10
Other liabilities	83	12	11	15	−15
Government relief funds	—	—	−9	−39	−38
Net cash provided by operating activities	132	130	462	381	374
Cash paid for acquisitions, net of cash acquired	−8	−54	−349,000	−10	−139
Cash paid for capital expenditures	−572	−690	−424	−296	−245
Proceeds from sale of property and equipment	24	10	29	7	3
Other	−90,000	−3	−2	−7	−1
Net cash used in investing activities	−556	−736	−397	−306	1,013
Borrowings on long-term debt	1,200	350	—	—	425
Principal payments on revolving credit facility	−1,035	−15	−35	−95	−330
Principal payments on long-term debt	−12	−56	−21	−19	−8
Repayment of long-term debt	−671	—	—	—	−2,228
Payment of debt issuance costs	−19	−2	—	—	−8
Repurchase of shares for payroll tax withholdings, net of proceeds from stock option exercises	−4	−1	−44	−6	16
Repurchase of common stock	−50	—	—	—	—
Contributions from noncontrolling partners in joint ventures	9	5	3	15	5
Distributions to noncontrolling partners in joint ventures	−4	−3	−5	−1	−2
Cash paid for contingent consideration	−2	—	—	—	—
Other	−90,000	—	37,000	52,000	−7
Net cash provided by (used in) financing activities	481	583	−63	−111	−1,637
Net increase (decrease) in cash and cash equivalents	57	−24	2	−36	−245
Cash paid for interest	125	113	81	66	94
Cash paid for income taxes	30	28	66	86	79
Assets acquired, excluding cash	54	59	7	11	176
Liabilities assumed	−893,000	−4	−128,000	−1	−37
Contingent consideration issued in connection with an acquisition	—	−2	—	—	—
Redeemable noncontrolling interest resulting from an acquisition	−45	—	−6	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro